Pembrolizumab/rivaroxaban interaction

Pembrolizumab/rivaroxaban interaction Reactions 1704, p304 - 2 Jun 2018 X S Intracerebellar haemorrhage: case report A 78-year-old man developed intracerebellar haemorrhage following concomitant use of pembrolizumab and rivaroxaban [durations of treatments to reactions onsets not stated]. The man had a history significant for rheumatoid arthritis, atrial fibrillation, coronary artery disease, hypertension, diabetes mellitus, and hypothyroidism. His ongoing medications included rivaroxaban for atrial fibrillation [dosage and route not stated] and prednisone for rheumatoid arthritis. In 2009, he presented with a forehead melanoma and underwent surgeries over a period of three years. In August 2016, the forehead melanoma re-appeared along with bilateral periparotid lymphadenopathy, hence he started receiving immunotherapy with IV pembrolizumab 2 mg/kg every three weeks. He received six doses of pembrolizumab over a period of 4 months. However, during the therapy he developed spontaneous intracerebellar haemorrhage. The man’s pembrolizumab therapy was discontinued in December 2016. Subsequently, his haemorrhage resolved without any further complications. The development of intracerebellar haemorrhage was considered to be due to excessive anticoagulation due to their impaired metabolism from pembrolizumab therapy. Author comment: "Factor Xa inhibitors are metabolized by the hepatic CYP3/A4 system; thus, any effects of PD-1 inhibitors on this enzyme might have implications for the metabolism of these novel anticoagulants. Thus, the underlying risk factors for potential interactions with immunotherapy should be assessed carefully and treatments should be individualized for every patient". Puri A, et al. The safety of pembrolizumab in metastatic melanoma and rheumatoid arthritis. Melanoma Research 27: 519-523, No. 5, Oct 2017. Available from: URL: http://doi.org/10.1097/CMR.0000000000000387 - USA 803323077 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Pembrolizumab/rivaroxaban interaction

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/pembrolizumab-rivaroxaban-interaction-FKkV5xHFHm
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46947-2
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p304 - 2 Jun 2018 X S Intracerebellar haemorrhage: case report A 78-year-old man developed intracerebellar haemorrhage following concomitant use of pembrolizumab and rivaroxaban [durations of treatments to reactions onsets not stated]. The man had a history significant for rheumatoid arthritis, atrial fibrillation, coronary artery disease, hypertension, diabetes mellitus, and hypothyroidism. His ongoing medications included rivaroxaban for atrial fibrillation [dosage and route not stated] and prednisone for rheumatoid arthritis. In 2009, he presented with a forehead melanoma and underwent surgeries over a period of three years. In August 2016, the forehead melanoma re-appeared along with bilateral periparotid lymphadenopathy, hence he started receiving immunotherapy with IV pembrolizumab 2 mg/kg every three weeks. He received six doses of pembrolizumab over a period of 4 months. However, during the therapy he developed spontaneous intracerebellar haemorrhage. The man’s pembrolizumab therapy was discontinued in December 2016. Subsequently, his haemorrhage resolved without any further complications. The development of intracerebellar haemorrhage was considered to be due to excessive anticoagulation due to their impaired metabolism from pembrolizumab therapy. Author comment: "Factor Xa inhibitors are metabolized by the hepatic CYP3/A4 system; thus, any effects of PD-1 inhibitors on this enzyme might have implications for the metabolism of these novel anticoagulants. Thus, the underlying risk factors for potential interactions with immunotherapy should be assessed carefully and treatments should be individualized for every patient". Puri A, et al. The safety of pembrolizumab in metastatic melanoma and rheumatoid arthritis. Melanoma Research 27: 519-523, No. 5, Oct 2017. Available from: URL: http://doi.org/10.1097/CMR.0000000000000387 - USA 803323077 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off